neoclarityn
n.v. organon - desloratadina - rhinitis, allergic, perennial; urticaria; rhinitis, allergic, seasonal - antihistaminice pentru uz sistemic, - neoclarityn este indicat pentru ameliorarea simptomelor asociate cu:alergice rhinitisurticaria.
ciprofloxacina claris 2mg/ml
orifarm generics a/s - danemarca - ciprofloxacinum - sol. perf. - 2mg/ml - chinolone antibacteriene fluorochinolone
dobutamina claris 12,5 mg/ml
peckforton pharmaceuticals limited - marea britanie - dobutaminum - conc. pt. sol. perf. - 12,5mg/ml - stimulante cardiace excl. glicozizi cardiotonici med.adrenergice si dopaminergice
clariscan 0,5 mmoli/ml
ge healthcare as - norvegia - acid gadotericum - sol. inj. - 0,5mmoli/ml - contrast media-rezonanta magnetica medii de contrast paramagnetice
clariscan 0,5 mmoli/ml
ge healthcare as - norvegia - acid gadotericum - sol. inj. in seringa preumpluta - 0,5mmoli/ml - contrast media-rezonanta magnetica medii de contrast paramagnetice
clariscan™ 279,3 mg/ml soluţie injectabilă
ge healthcare as - acidum gadotericum - soluţie injectabilă - 279,3 mg/ml
vabysmo
roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - oftalmologice - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).
byooviz
samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmologice - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ximluci
stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologice - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologice - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).